Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines to treat life-altering central nervous system disorders. The company's principal product candidate is ZULRESSO? (brexanolone) injection, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's other product candidate is SAGE-217, an oral compound that is being developed for PPD and major depressive disorder. The company also has a portfolio of other compounds that target GABAA receptors, which include SAGE-324 and SAGE-689. The company's second area of focus is the development of compounds that target the NMDA receptor, which include SAGE-718.
  • TickerSAGE
  • ISINUS78667J1088
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Sage Therapeutics Inc: 2 directors

Two Directors at Sage Therapeutics Inc bought/maiden bought 26,642 shares at between 56.047USD and 56.321USD. The significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restric...

Kenneth Shields ...
  • Laura Chico

Going Over The WATERFALL Results - We Still Think There's A Path Forward

Kenneth Shields ...
  • Laura Chico

When A WATERFALL Beats A MOUNTAIN

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the 200-day moving average. This level is roughly 2,817 on the S&P 500 and roughly 1,000 on the S&P 600 Small Cap index. Some consolidation or a mild pullback is possible in the near-term, which we believe would help alleviate current overbought readings and allow for a more orderly and meaningful move higher. This constructive outlook is supported by the themes highlighted below: • Internals are healthy. The S&P 500 advance/decline line is advancing to ne...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Sage Therapeutics Inc: 2 directors

Two Directors at Sage Therapeutics Inc bought/maiden bought 26,642 shares at between 56.047USD and 56.321USD. The significance rating of the trade was 94/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restric...

Kenneth Shields ...
  • Laura Chico

Going Over The WATERFALL Results - We Still Think There's A Path Forward

Kenneth Shields ...
  • Laura Chico

When A WATERFALL Beats A MOUNTAIN

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

SAGE THERAPEUTICS sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of SAGE THERAPEUTICS (US), a company active in the Biotechnology industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 1 out of 4 possible stars while its market behaviour can be considered as defensive. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date May 14, 2021, the closing price was USD 70.86 and its potential was estimated at USD 92.26.

37 Stocks for March 2018 (Full Report)

We highlight stocks that demonstrate solid growth at a reasonable price (GARP). Stocks selected for our model portfolio strategies all rank highly for the following metrics, with an emphasis on proxies for cash flow growth and ROIC:  Relative Value Operating Momentum Analyst Revision Momentum Fundamental Quality Pages 7-3 contain brief commentary and highlights of a few stocks that seem particularly attractive.     Page 14 contains rebalancing actions for our long-only model portfolio. Page 16 contains rebalancing actions for our short-only model portfolio. Target and stop prices, ...

40 Stocks for February 2018

This report was originally published on Feb 5, 2018. It followed an abbreviated note that was issued prior to the close on January 31, 2018. Long/Short Model Portfolio Monthly Update: January 31, 2018There are limitations inherent in our theoretical model results, particularly with the fact that such results do not represent actual trading and they may not reflect the impact material economic and market factors might have had on our decision making if we were actually managing client money. Please see additional disclaimers and disclosures at the back of this report.We highlight stocks that d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch